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a b s t r a c t
Background: Vascular risk factors such as atherosclerosis, diabetes, and elevated homocysteine levels are strongly
correlated with onset of Alzheimer’s disease (AD). Emerging evidence indicates that blood coagulation protein
thrombin is associated with vascular and non-vascular risk factors of AD. Here, we examined the eﬀect of thrombin
and its direct inhibitor dabigatran on key mediators of neuro-inﬂammation and AD pathology in the retinoic acid
(RA)-diﬀerentiated human neuroblastoma cell line SH-SY5Y.
Methods: SH-SY5Y cells exposed to thrombin concentrations (10–100 nM) +/- 250 nM dabigatran for 24 h were
analyzed for protein and gene expression. Electrophoretic mobility shift assay (EMSA) was used to determine DNA
binding of NFkB. Western blotting, qRT-PCR and ELISA were used to measure the protein, mRNA, and activity
levels of known AD hallmarks and signaling molecules.
Results: Dabigatran treatment attenuated thrombin-induced increase in DNA binding of NF𝜅B by 175% at 50 nM
and by 77% at 100 nM thrombin concentration. Thrombin also augmented accumulation of A𝛽 protein expression
and phosphorylation of p38 MAPK, a downstream molecule in the signaling cascade, expression of pro-apoptotic
mediator caspase 3, APP, tTau and pTau. Additionally, thrombin increased BACE1 activity, GSK3𝛽 expression,
and APP, BACE1, Tau and GSK3𝛽 mRNA levels. Co-incubation with dabigatran attenuated thrombin-induced
increases in the protein, mRNA, and activities of the aforesaid molecules to various extents (between −31% and
−283%).
Conclusion: Our data demonstrates that thrombin promotes AD-related pathological changes in neuronal cultures
and suggests that use of direct oral anticoagulants may provide a therapeutic beneﬁt against thrombin-driven
neuroinﬂammation and downstream pathology in AD.

1. Introduction
Alzheimer’s disease (AD) is a progressive neurological disorder involving aberrant protein processing characterized by both intraneuronal
protein aggregates of hyperphosphorylated tau (neuroﬁbrillary tangles)
and extracellular protein aggregates (senile plaques) composed of amyloid beta (A𝛽) [1]. Additionally, vascular dysfunction and neuroinﬂammation have been consistently demonstrable in AD pathology [2]. Several population based studies have highlighted the association between
vascular risk factors such as hypertension and diabetes with the onset
of AD. Up to 84% of aged subjects show morphological substrates of
cerebrovascular disease in addition to AD pathology [3]. Vascular co-

morbidity has been established as a risk factor for the onset of AD in
40% -80% of AD patients [4]. Various research groups have documented
inﬂammation as an invariant feature and a likely driver of pathologic
processes in the AD brain. Large-scale genome-wide association studies
point out several genetic variants linked to neuroinﬂammation suggesting that neuroinﬂammation is a common nexus for the onset of many
underlying pathologies of A [5].
Numerous inﬂammatory mediators are elevated in the AD brain microvasculature including tumor necrosis factor alpha (TNF𝛼), transforming growth factor-𝛽 (TGF𝛽), interleukins (ILs) and the multifunctional
inﬂammatory protein thrombin [6,7]. Thrombin is especially relevant
for AD due to its ability to trigger both tau and A𝛽 accumulation as
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well as to stimulate proinﬂammatory signaling cascades. Thrombin has
been implicated as a mediator of interest in AD since the 90swhen it was
detected in senile plaques and in neuroﬁbrillary tangles [8,9]. Elevated
levels of thrombin as well as its speciﬁc receptor, PAR-1, have been identiﬁed in the AD brain [10,11]. Persistent thrombin signaling induces
tau aggregation and related hippocampal degeneration [12,13]. There
is cross talk between A𝛽 and thrombin where A𝛽promotes thrombin
generation through factor XII-mediated factor XI activation and thrombin induces secretion of amyloid precursor protein (APP) [14]. Thrombin can also regulate many of the proinﬂammatory signaling mechanisms relevant for AD including NF𝜅B and mitogen activated protein
kinases(MAPKs).The transcription factor NF𝜅B is considered a primary
regulator of inﬂammatory processes and several studies have shown that
inhibiting NF𝜅B pathway attenuates neuroinﬂammation [15,16]. NF𝜅B
signaling has been also implicated as a factor that is abundant in neurons
as well as in microglia and plays a pivotal role as a transcriptional factor
of various AD associated genes [17,18]. Postmortem studies examining
brains from AD patients demonstrated upregulation of NF𝜅B activity in
cells involved in the neurodegenerative process [19]. In addition, increased immunoreactivity of NF𝜅B- p65 in neurons and astrocytes in
the proximity of A𝛽 plaques has been documented [20,21].
Furthermore, in vivo studies have reported that the 𝛽-site APP cleaving enzyme 1 (BACE1) promoter contains an NF𝜅B binding element and
that overexpressed A𝛽 stimulates BACE1 promoter activity via NF𝜅Bdependent pathways [22]. Like the involvement of NF𝜅B in many ADrelated processes, MAPKs have been also implicated in AD signaling cascades. In this regard, A𝛽 toxicity, tau hyperphosphorylation, apoptosis
and deregulated autophagy have been partly attributable to MAPK and
MAPK signaling [23]. The p38 MAPK is of special interest due to its
involvement in the regulation of A𝛽 toxicity, glutamate excitotoxicity,
disruption of synaptic plasticity and NF𝜅B activation [23].
The pleiotropic eﬀects of thrombin in several cell types on proinﬂammatory signaling pathways including NF𝜅B and MAPK, suggests
that thrombin could contribute to pathological events in the AD brain.
This idea is supported by studies showing that inhibiting thrombin reduces AD pathology. A recent study showed that treatment of TgCRND8
transgenic AD mice with the direct thrombin inhibitor dabigatran improved spatial memory deﬁcits, reduced neuroinﬂammation and amyloid plaque formation [24]. We have previously documented that dabigatran reduces oxidative and inﬂammatory stress in the brain microvasculature of the triple transgenic AD mouse model [25]. Although these
data demonstrate beneﬁcial eﬀects of inhibiting thrombin in the whole
brain and cerebral vasculature, respectively, the possible direct eﬀects
on AD-related pathology in neurons has not been determined. The objective of the current study is to determine the eﬀects of thrombin in the
presence or absence of dabigatran on key mediators of neuroinﬂammation and AD pathology in the retinoic acid (RA) diﬀerentiated SH-SY5Y
neuronal cell line.

to diﬀerentiation medium consisting of DMEM/F-12 medium supplemented with, 1% FBS, 1 mM l-glutamine, 100 U penicillin/mL, 100 𝜇g
streptomycin/mL and 10 𝜇M of all-trans-retinoic acid (Sigma Aldrich,
MO). The diﬀerentiation medium was changed every 3rd day for the
duration of 7 days. Treatment medium consisted of DMEM (Invitrogen,
CA) containing 1% Bovine Serum Albumin (BSA, Sigma Aldrich, MO),
sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2
mM L-glutamine. Diﬀerentiated cells were treated with 0, 10, 50, and
100 nM human alpha-thrombin (EMD Millipore, MA), with or without
dabigatran (250nM) for 24 h at 37°C in a 5% CO2 incubator. Concentration of the dabigatran stock solution was 1 mM (dissolved in DMSO),
whereas the concentration of the thrombin stock solution was 10μM
(dissolved in sterile water). The concentration of DMSO in the cell culture media was maintained at 0.1% for control and across all treatment
groups.
2.3. Preparation of total cell extract
Following treatment, the cells were rinsed with cold phosphate
buﬀer saline (PBS, pH 7.4) and harvested and lysed in radioimmunoprecipitation assay (RIPA) buﬀer (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate) containing 1% protease and phosphatase inhibitors
(Sigma Aldrich, MO), followed by incubation on ice for 30 min. The
cell debris was removed by centrifugation at 10,000 g for 10 min at 4°C
and the supernatant was collected, protein concentration was quantiﬁed
by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL)
2.4. Nuclear protein extraction and Electrophoretic Mobility Shift Assay
(EMSA)
Using the NE-PER Nuclear Cytoplasmic Extraction Reagent kit
(Pierce, Rockford, IL), nuclear extracts were prepared according to the
manufacturer’s instruction. Treated cells were rinsed with cold PBS
and centrifuged at 500 g for 5 min. The resulting cell pellet was suspended in 200 𝜇L of cytoplasmic extraction reagent I by vortexing. This
was followed by incubation of the suspension on ice for 10 min and
11 𝜇L of a second cytoplasmic extraction reagent II was added, vortexed for 5 s, incubated on ice for 1 min and centrifuged for 5 min
at 16,000 g. The cytoplasmic extract (supernatant fraction) was transferred to a pre-chilled tube. The insoluble pellet fraction, containing
crude nuclei, was resuspended in 100 𝜇L of nuclear extraction reagent
by vortexing for 15 s and incubated on ice for 10 min followed by
centrifugation for 10 min at 16, 000 g. The resulting supernatant, constituting the nuclear extract, was used for subsequent experiments.
EMSA was performed in accordance with the manufacturer’s protocol
for Light Shift Chemiluminescent EMSA kit (Thermo-Fisher, MA). Single stranded 3’-biotin labeled consensus oligonucleotides for NF⊇𝛽 5´AGTTGAGGGGACTTTCCCA GGC-3 was purchased from Integrated DNA
Technologies (Coralville, IA). DNA binding reactions were performed in
20 𝜇L reaction mix containing biotin-labeled oligonucleotides and nuclear extracts. Additional unlabeled oligonucleotides were added for
competition. Reaction products were then separated by electrophoresis. Thereafter, the protein-DNA complexes were transferred onto a positively charged nylon membrane (Millipore, MA) and detected by chemiluminescence.

2. Material and methods
2.1. Cell culture
Human neuroblastoma cells (SH-SY5Y) procured from American
type cell culture (ATCC, VA) were seeded at a density of 27 × 103 in cell
culture ﬂask for routine culture. Cells were cultured in growth medium
consisting of Dulbecco’s Modiﬁed Eagle Medium (DMEM)/F12 medium
(Invitrogen, MD) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin, 100 𝜇g/ml streptomycin, and 2 mM L-glutamine
in a humidiﬁed atmosphere of 5% CO2 in air at 37 °C.

2.5. Western blot
Protein extracts from diﬀerent treatment groups were mixed with
equal volumes of sodium dodecyl sulphate (SDS) buﬀer [0.125 M Tris–
HCl, pH 6.8, 2% SDS, 0.5% (v/v) 2-mercaptoethanol, 1% bromophenol
blue, and 19% glycerol] and boiled for 5 min. For determining the protein expressions, 30𝜇g of the total protein was resolved by SDS-PAGE on
4-20% Novex gradient gels (Invitrogen, CA) at 90V constant under reducing conditions and transferred using dry blotting (iBlot, Invitrogen,

2.2. SH5Y diﬀerentiation and treatments
Cells at the density of 106 cells/ml were sub-cultured in 100mm culture dishes (Cyto-one, USA Scientiﬁc, FL) containing 5 ml each of growth
media. Twenty-four hours (h) after seeding, the medium was changed
2
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Table 1
List of primary antibodies used for the western blot analysis.
Antibody/ Catalog number

Source

Supplier

APP (E8B3O) XP/ 29765 S
Tau (Tau-46)/ 4019S
Phospho-Tau (Thr181) (D9F4G)/ 12885S
Phospho-Tau (Ser404) (D2Z4G)/20194S
p38 MAPK (D13E1) XP/8690S
Phospho-p38 MAPK (Thr180/ Tyr182) (D3F9) XP/ 4511S
Caspase-3 (D3R6Y)/14220S
𝛽-Actin (8H10D10)/ 3700S

Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Mouse

Cell
Cell
Cell
Cell
Cell
Cell
Cell
Cell

Signaling
Signaling
Signaling
Signaling
Signaling
Signaling
Signaling
Signaling

Technology
Technology
Technology
Technology
Technology
Technology
Technology
Technology

Isotype

Dilution

IgG
IgG1
IgG
IgG
IgG
IgG
IgG
IgG2b

1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:3000

Table 2
Primers used in qPCR for the measuring gene expresssion.
Gene

Sense Strand

Anti-Sense Strand

APP
BACE1
GSK3𝛽
MAPT
𝛽-actin

5- GCCAAAGAGACATGCAGTGA-3
5-AGGGAGCATGATCATTGGAG-3
5-ATTACGGGACCCAAATGTCA-3
5-AAGATCGGCTCCACTGAGAA -3
5-GGGAAATCGTGCGTGACAT-3

5′- CCAGACATCCGAGTCATCCT´-3′
5′-AACACTTTCTTGGGCAAACG-3′
5’-TGCAGAAGCAGCATTATT GG-3’
5´- GGACGTGGGTGATATTGTCC -3´
5’-CAGGAGGAGCAATGATCTTG-3

CA). Non-speciﬁc binding was blocked by incubating the PVDF membrane with 5% BSA in Tris-buﬀered saline with 0.05% Tween 20 (TBS-T)
with gentle shaking for 1 h at room temperature (RT). Immunoblotting
was performed after overnight exposure to the antibodies (Cell Signaling Technology, MA) listed in Table 1, diluted in TBST with gentle agitation on a shaker at 4°C. On the following day the membranes were
exposed for 1 h to IRDye® 680 LT or IRDye® 800LT infrared dye (LICOR Biotechnology, NE) goat anti-mouse/goat anti-rabbit diluted at 1:
10,000 after washing with TBS-T. Finally, Odyssey® Infrared Imaging
System (Li-COR Biotechnology, NE) was used to detect and quantify infrared signal of protein bands. Loading of the samples was assessed by
staining the gels with Bio-safe Coomassie blue stain (Bio-Rad, CA) after
the transfer to PVDF membranes.

zymatic reaction for measuring secretase levels was carried out in an
anti-BACE1-coated 96-well plate. Assay standards and 100 𝜇g of protein
samples in 100 𝜇L of 1X Assay Diluent were added to 96-well plates. The
wells were covered and incubated for 2.5 h at RT with gentle shaking.
The solution was aspirated from the wells and washed four times with a
wash buﬀer. This was followed by the addition of 100μL of 1X prepared
biotinylated antibody to each well and incubated for 1 h at RT with
gentle shaking. The solution was pipetted out and wells were washed
four times with a wash buﬀer. Afterwards 100μL of Streptavidin-HRP
solution was pipetted in each well and incubated for 45 min at RT with
gentle shaking. After discarding the solution and washing the wells 4
times with a wash buﬀer 100μL of TMB substrate was added to each
well followed by incubation for 30 min at RT in the dark with gentle
shaking. Lastly, 50 μl of Stop Solution to each well and the absorbance
was measured at 450nm and 550 nm using a plate reader. The levels of
BACE1 were presented in nanograms per milliliter (ng/ml).

2.6. Enzyme-linked immunosorbent assays for A𝛽 (1–42) and BACE1
levels
The levels of A𝛽 were measured in cell lysate and in conditioned
media using human A𝛽 (1–42) assay kit. The conditioned media was
concentrated using spin columns (Thermo-scientiﬁc, MA) prior to use.
Protein concentration of the column media concentrate, and cell lysate
was determined by BCA protein assay (Pierce, Rockford, IL). This ELISA
kit is based on solid-phase sandwich enzyme-linked immunosorbent assays with two kinds of highly speciﬁc antibodies, which are 100% reactive with human A𝛽 (1–42). The assay was conducted according to the
manufacturer’s instructions (Immuno-Biological Laboratories, Gunma,
Japan) with minor modiﬁcations. Assay standards and 100 𝜇gof protein sample in 100 𝜇L of EIA buﬀer were added to 96-well plates precoated with anti-human A𝛽 IgG monoclonal antibody. The plates were
incubated overnight at 4°C and were washed seven times using the 40X
diluted wash buﬀer supplied with the kit (0.05% Tween 20 in phosphate buﬀer). Next, 100 𝜇L labeled antibody was added to the samples and standards, followed by incubation at 4°C for 1 h. After incubation, the plates were washed nine times followed by the addition of
100 𝜇L tetramethyl benzidine (TMB) as a coloring agent. The plates
were incubated in the dark for 30 minutes at room temperature. Lastly,
100 𝜇L of stop solution was pipetted in each well to stop the reaction, and absorbance was measured at 450 nm using a Spectra Max
UV/Vis Spectrometer (GMI, Inc.). The levels of A𝛽 in the test samples were calculated relative to the standard curve generated for each
plate.
BACE1 levels were measured with a Human Beta-secretase-1 ELISA
Kit (Invitrogen, CA) according to the manufacturer’s protocol. The en-

2.7. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis
The SH-SY5Y cells were treated as mentioned above. Cells were harvested and the total RNA was extracted using TRIzol reagent (Invitrogen,
CA) according to the manufacturer’s protocol. RNA concentrations were
estimated using the Nanodrop (Thermo Scientiﬁc, DE). First-strand complementary DNA (cDNA) was synthesized from 1.5 𝜇g of total RNA using
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) as described earlier [26]. The PCR reaction (40 cycles) were carried out using a SYBR
green PCR master mix (Applied Biosystem, CA) and was performed using the ViiA7 Real-Time PCR system (Applied Biosystem). Table 2 shows
the list of Sense and anti-Sense primers designed using Primer-3 plus.
Expression data were reported using 2-⊗⊗ Ct method and 𝛽-actin mRNA
as endogenous control.
2.8. Statistical analysis
Western blot bands were quantiﬁed by using the LI-COR/ Odyssey
infrared image system. All measurements were made in triplicate and
all values are presented as mean ± standard error of the mean (S.E.M).
The signiﬁcance of the diﬀerence among means of the experimental
groups was obtained with one-way analysis of variance, the TukeyKramer multiple-comparison post-test, and the student Newman-Keuls
comparison post-test, using GraphPad Prism version 8.0 computer software (La Jolla, CA, USA). The level of signiﬁcance was set at p < 0.05.
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Fig 1. Dabigatran attenuates thrombin concentrationdependent NF-/B p65 DNA-binding activity.
Nuclear extract of RA diﬀerentiated SH5Y cells treated with
a series of thrombin concentrations (0-100nM) with or without dabigatran (250 nM) for 24 h, were incubated with the
biotin-labeled oligonucleotides probe corresponding to binding of NF/B and subjected to Electrophoresis Mobility Shift
Assay. Untreated cells were used as Control. (A) Representative DNA: protein shifts for dabigatran (-) and dabigatran
(+). (B) Quantiﬁcation of bound to free DNA determined that
thrombin induced concentration dependent higher association
of nuclear proteins with the NF𝜅B. ∗ ∗ p < 0.05, ∗ ∗ ∗ p < 0.001.
Data are represented as mean± SEM, n = 3 (represent three
independent experiments).

expression of p38 at 50nM (p < 0.01, 46.51% ± 1.60%) and 100nM
(p < 0.001, −84.87 ± 4.75%), Reduction in the protein expression of
Pp38 was observed at 50nM (p < 0.01, −52.83% ± 5.26%) and at 100nM
(p < 0.001, −115.46% ± 17.46%) by dabigatran co-treatment (Fig. 2B
and C).
Expression of the apoptosis-related protein, caspase-3 increased with
50 nM and 100 nM thrombin exposure (p < 0.05, 29.56% ± 3.86% and
p < 0.01, 49.33% ± 7.67%) compared to control, which was signiﬁcantly
(p < 0.01, −64.33 ± 1.01% and p < 0.001, −98.26 % ± 4.53%) reversed
by inclusion of 250 nM dabigatran in the treatments (Fig. 2D).

3. Results
3.1. Dabigatran attenuates thrombin-induced NF/B activation
The impact of dabigatran on thrombin-induced activation of NF/B
was studied in the nuclear extract of RA diﬀerentiated SH-SY5Y cells
by EMSA. Our results show a signiﬁcant up-regulation of NF𝜅B DNAbinding after 24 h exposure to a series of thrombin concentrations
(10–100 nM), compared to untreated control cells (Fig 1A). Diﬀerentiated SH-SY5Y cells exposed to thrombin and co-treated with dabigatran
(250nM) displayed a signiﬁcant decrease in NF/B activation (reduced
NF𝜅B DNA-binding) at 50nM (p < 0.01; −175.11% ± 26.24% and 100
nM (p < 0.05; −77.05% ±14.60%) compared to cells treated with only
thrombin. No eﬀect on NF/B activation was observed when cells were
exposed to dabigatran (250nM) alone (Fig. 1B). These results were veriﬁed by western blot that showed a similar trend of reduced expression of
NF𝜅B in cells co-treated with thrombin and dabigatran (data not shown).

3.3. Dabigatran attenuated APP protein expression as well as BACE1 and
A𝛽 levels in neuronal cells exposed to thrombin
APP protein expression was increased by all concentrations of thrombin and signiﬁcantly (p < 0.01, 53.51% ± 3.70%) at the 100 nM, that
was signiﬁcantly reverted to control levels by co-treatment with 250
nM dabigatran (p < 0.05, − 68.28% ± 18.61%) (Fig. 3B). A similar pattern was demonstrable for expression levels of A𝛽 1-42 in cell lysate
(Fig. 3C) as well as in conditioned media (Fig. 3D). Thrombin increased
expression of A𝛽 1-42 in both lysate (p < 0.01, 102.39% ± 21.20%) and
conditioned media (p < 0.05, 87.03% ± 19.21%) only at 100 nM concentration. Cotreatment of dabigatran signiﬁcantly attenuated thrombin
response in lysate (p < 0.05, −91.04% ± 7.0%) as well in conditioned
media (p < 0.05, −55.18%), signiﬁcant reduction was only observed in
cell exposed to 100 nM thrombin.
Enzyme-linked immunosorbent assay was used to evaluate the
changes in the levels of BACE1 in cell lysate. Levels of BACE1 were
signiﬁcantly elevated in diﬀerentiated SH-SY5Y cells exposed to thrombin concentrations of 50nM (p < 0.05, 43.19% ± 6.52%) and 100 nM
(p < 0.05, 35.39% ± 5.57%) for 24 h. As was observed with APP and A𝛽
1-42, dabigatran signiﬁcantly (p < 0.05, −51.57%±5.94%) decreased

3.2. Expression of neuroinﬂammation-related signaling proteins and
proapoptotic protein increased by thrombin is blocked by dabigatran
Western blot analysis using antibodies directed against p38 and the
phosphorylated form of p38 (Pp38) were used to study the expression
of these signaling proteins in the neuroblastoma cell line. RA diﬀerentiated SH-SY5Y cells were exposed to a series of thrombin concentrations
(10-100 nM) with or without dabigatran (250 nM) (Fig 2A). Thrombin increased expression of the target proteins, but the eﬀective dose
was variable. For p38, insigniﬁcant increase was observed at 50 nM but
was statistically signiﬁcant at 100 nM thrombin (p < 0.001, 61.36% ±
10.77%). On the other hand, thrombin signiﬁcantly increased the expression of Pp38 at 50nM (p < 0.01, 55.42 ± 10.25%) and 100 nM
(p < 0.001, 105.3% ± 20.36%) concentrations. Treatment of dabigatran in thrombin-exposed cells signiﬁcantly lowered signaling protein
4
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Fig 2. Dabigatran alleviates thrombin induced dose-dependent change in p38 MAPK, P38 MAPK and Caspase 3.
RA diﬀerentiated SH5Y were pre-incubated with thrombin (10nM, 50nM and 100nm) with (+) or without (-) dabigatran (250 nM) for 24h h in treatment medium.
Protein expression was measured by western blotting as stated in section 2.4. (A) Representation of the protein expressions of p38, Pp38, Caspase3 and housekeeping
protein ®-actin. (B-D) Individual data points are represented on the graph, as well as the means for each time point (n = 3) and signiﬁcance is represented as
∗p < 0.01, ∗∗p < 0.05, ∗∗∗p < 0.001 compared to untreated control, +p <+ 0.01 compared to 50nM thrombin, ###p < 0.001 compared 100nM thrombin.

Fig 3. Dabigatran rectiﬁes thrombin-induced change in the expression or levels of proteins associated with amyloid pathway.
RA diﬀerentiated SH5Y were pre-incubated with thrombin (10nM, 50nM and 100nm) with (+) or without (-) dabigatran (250 nM) for 24h h in treatment medium.
Western blotting and ELISA were carried out for the measurement of protein levels. (A) Immunoblot representation of APP protein expressions, (B) Quantiﬁcation of
APP western blot bands normalized to 𝛽-actin, (C-E) A𝛽-42 and BACE1 levels were determined by ELISA. Histograms represent quantiﬁcation of protein expression
and chemilucent signal. Data shown are the mean ± SEM (n = 3) and signiﬁcance is represented as ∗p < 0.05, ∗∗p < 0.01 compared to untreated control, +p <+ 0.05
compared to 50nM thrombin, #p < 0.05 compared 100nM thrombin.

BACE1 levels, which was statistically signiﬁcant at 100 nM thrombin
concentration (Fig. 3E).

SH-SY5Y cells exposed to various concentrations of thrombin (Fig. 4A).
Thrombin treatment resulted in a signiﬁcant increase in tTau at 50nM
(p < 0.01, 64.64% ± 19.11%) and 100 nM (p < 0.01, 85.95% ± 20.36%)
compared to untreated control. Co-treatment of cells with dabigatran
signiﬁcantly (p < 0.05, −45.08% ± 19.66%) alleviated the increased
expression of tTau protein evoked by 100 nM thrombin (Fig. 4B). Antibodies directed against select serine and threonine residues were used
to evaluate the eﬀect thrombin on site-speciﬁc phosphorylated species

3.4. Dabigatran lowers expression of total tau and phosphorylated tau
species induced by thrombin
Levels of total tau (tTau) protein as well as the site-speciﬁc phosphorylated (pTau)species Tau-Ser-404 and Thr-181 were evaluated in
5
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Fig 4. Dabigatran treatment reduces thrombin induced Total Tau and site-speciﬁc Tau Phosphorylation.
RA diﬀerentiated SH5Y were pre-incubated with thrombin (10nM, 50nM and 100nm) with (+) or without (-) dabigatran (250 nM) for 24h h in treatment medium.
Protein expression was measured by western blotting as stated in section 2.4. (A) Representative Tau and site-speciﬁc tau (Ser-404 and Thr-181) proteins levels. The
RIPA cell lysate was used, and proteins were measured by western blot analysis as described in the methods section. (B-D) Histograms represent quantiﬁcation after
normalization to 𝛽-actin levels. Data shown are the mean±SEM (n = 3) and signiﬁcance are represented as ∗∗p < 0.01, ∗∗∗p < 0.001 compared to untreated control,
+p <+ 0.05, +p <+ 0.01 compared to 50nM thrombin, ###p < 0.001 compared 100nM thrombin.

of APP, BACE1, tau and GSK3𝛽 normalized to 𝛽-actin, were evaluated
by PCR in control and thrombin exposed cells treated with or without
dabigatran. Our results indicated that thrombin at 50 nM (p < 0.01,
160.86% ± 7.59%) and 100 nM (p < 0.01, 150.97% ± 29.21%) caused
a signiﬁcant upregulation in mRNA levels for APP (Fig. 6A), BACE 1 at
50nM (p < 0.01, 84.30% ± 31.48%) and 100nM (p < 0.001, 149.69%
± 25.82%) (Fig. 6B) and tau at 50nM (p < 0.05, 106.85% ± 16.73%)
and 100nM (p < 0.05, 132.22 % ± 37.77%) (Fig. 6C), whereas thrombin was able to elicit a signiﬁcant increase of GSK𝛽 mRNA levels even
at 10 nM (p < 0.05, 130.57% ± 9.97%), increase was also observed at
50nM (p < 0.001, 250. 20% ± 27.85%) and 100nM (p < 0.001, 270.94%
± 33.06%) (Fig. 6D). For all four AD-related mediators, dabigatran was
able to signiﬁcantly mitigate the increase in message evoked by thrombin.

pTau Ser-404 and pTau Thr-181. The eﬀect of thrombin on these phosphorylated tau species was like that observed for tTau. Thrombintreated cells displayed signiﬁcant increase in the protein expression of
pTau Ser-404 at 50nM (p < 0.001, 160.62% ± 8.91%) and 100 nM
(p < 0.001, 130.28 ± 20.09%), signiﬁcant increase in protein expression of pTau Thr-181 was also observed in cells exposed to thrombin at
50nM (p < 0.001, 108.52% ± 25.38%) and 100nM (p < 0.001, 82.67% ±
5.81%) compared to non-treated control. Co-treatment with dabigatran
was able to mitigate the thrombin-induced elevation in pTau Ser-404 at
50 nM (p < 0.05, −101.79% ± 4.81%), whereas pTau Thr-181 was reduced signiﬁcantly (p < 0.001, −102.74% ± 2.68% ) at 100 nM (Fig. 4C
and D).
3.5. Dabigatran modulates thrombin-induced kinases protein expression
We explored the eﬀects of thrombin on GSK-3𝛽, a kinase implicated in AD pathogenesis by its multiple eﬀects on tau phosphorylation, amyloid-𝛽 production, memory, neurogenesis, and synaptic function. Treatment of the neuroblastoma cell line SH-SY5 with thrombin
evoked an increase in GSK-3𝛽 expression that was signiﬁcant at 50nM
(p < 0.01, 180.30% ± 11.35%) and at 100 nM thrombin (p < 0.001,
250.98% ± 17.88%) (Fig. 5A). Exposure of cells to dabigatran reduced
GSK-3𝛽 levels that were statistically signiﬁcant at 50nM (p < 0.001,
−196.44% ± 11.24%) and 100nM (p < 0.001, −283.78% ±11.24%) as
compared to thrombin treated counterparts (Fig. 5B).

4. Discussion
The serine protease thrombin, associated with coagulation and inﬂammation, has the potential to orchestrate adverse series of cellular
events mediated through activation of its widely expressed proteaseactivated receptors (PARs) [27]. Accumulating evidence has shown an
association between elevated thrombin levels and increased PAR activity in AD brains suggesting a contributory role in disease onset and/or
progression [10,11]. Previously we have shown that administration of
thrombin directly in rat brains induced neuronal cell death, glial scarring, and cognitive deﬁcits in these rat brains [28]. Thrombin inhibition is a new tactic that has been proposed to curb the noxious cycle of feed-forward cycle responsible for the onset of neuroinﬂammation in AD [29]. Dabigatran, a member of the direct oral anticoagulants (DOACs) family of thrombin inhibitors, is widely utilized for sev-

3.6. Eﬀect of dabigatran on AD-related gene expression in thrombin
exposed diﬀerentiated SH-SY5Y cells
We further explored whether the eﬀect of thrombin on protein expression was also demonstrable at the transcriptional level. mRNA levels
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studies by Igarashi and colleagues demonstrated the potential of thrombin in cleaving puriﬁed full-length APP at a site just upstream from the
amino terminus of the A𝛽 domain between residues Arg556 and Ile567
[35]. Consistent with earlier research, our data revealed elevated APP
protein expression and upregulated APP and BACE1 gene levels following exposure to a series of thrombin concentrations for 24 h. A®-42
and BACE1 levels measured by ELISA revealed a similar increase in
their levels. Treatment of cells with dabigatran (250nM) attenuated the
increased levels of APP protein and downregulated APP mRNA, these
changes were also reﬂected by a signiﬁcant decrease in the levels of
BACE1 and A®-42 in cell lysate and conditioned media. Accumulating evidence from basic and clinical research indicate inﬂammation induced by A®has been implicated in neuronal degeneration [36,37]. It
has been reported that the levels of proinﬂammatory cytokines are signiﬁcantly elevated in brains of AD patients, which suggests that inﬂammation might contribute to the pathogenesis of AD [38]. A vicious cycle
of inﬂammation between A𝛽 accumulation, activated microglia, and microglial inﬂammatory mediators enhances A𝛽 deposition and neuroinﬂammation [39]. Our ﬁndings show that thrombin is involved independently in both arms of the pathological cascade, namely, inﬂammation
and A𝛽 formation, which can create a feed forward pathological cycle.
Activation of protease cascades within neurons has been associated
with cell death by apoptosis. Thrombin has been identiﬁed to play a
pivotal role in tissue injury by initiating an apoptotic mechanism coupled with activation of its receptor, PAR‐1 [40]. Smirnova et.al demonstrated initiation of apoptosis in neuronal cell line exposed to nanomolar thrombin concentrations that was associated with increased levels
of caspase-3 [40]. Seminal studies by Choi and coworkers demonstrated
increased loss of dopaminergic neurons in the substantia nigra of rodents that were intracranially exposed to thrombin. Same results were
also shown in mesencephalic cultures, following treatment with thrombin [41]. Similarly, Yuan and colleagues reported A𝛽 aggregation and
activation of caspase-3 in the mouse neuroblastoma cell line expressing double-mutated human APP and PS1 [42]. Consistent with other
research groups, our results also indicated a concentration dependent
increase in protein and mRNA levels of caspase 3, which was attenuated by co-treatment with dabigatran.
A𝛽-induced elevated Tau-phosphorylation and modiﬁed Tau conformation has been often linked with GSK3𝛽 activation [40]. In agreement
with earlier reports, our data showed thrombin signiﬁcantly elevated
the protein and mRNA levels of GSK3𝛽 at 100nM concentration. Concurrent with increased GSK3𝛽 expression, t Tau as well as site-speciﬁc
phosphorylation at p Tau Ser-404 (Fig 5C) and p Tau Thr-181 (Fig 5D)
were increased by thrombin. These changes were also associated with an
increase in the tau mRNA levels. Our results are in agreement with studies carried out by Suo et.al, who showed thrombin treated immortalized
hippocampal neuronal cells (HT22 cells) displayed the development of
thioﬂavin-S positive tau aggregates within 24 h, followed by an escalation in cell death at 72 h [13]. Our data revealed RA diﬀerentiated cells
with prior exposure to thrombin and subsequently treatment with dabigatran reduced GSK3𝛽 mRNA and protein levels. These changes were
also manifested by decrease in the tTau levels as well as site speciﬁc
phosphorylation.
Neuroinﬂammation has been postulated as the common portal for
the onset of many underlying pathologies of AD. Many of the key events
namely, A𝛽 toxicity, tau hyperphosphorylation, apoptosis and deregulated autophagy have been partly explained by the activation MAPKs
particularly p38 MAPK, justifying p38 MAPK as a potential target to
break the vicious A𝛽 toxicity cycle [23]. In this study, thrombin induced
signiﬁcant increase in the expression of p38 and its phosphorylated isoform in RA-diﬀerentiated human neuroblastoma cells (Fig 2A and B).
Several research groups have demonstrated that arresting p38 activity attenuates the transcriptional activity of the proinﬂammatory transcription factor NF𝜅B [43]. Our data support these ﬁndings as we also
observed decreased p38 MAPK expression in thrombin exposed SH5Y
cells treated with dabigatran, these changes correlated with reduction

Fig 5. GSK3® protein expression after Dabigatran treatment in thrombin exposed human neuroblastoma cells.
RA diﬀerentiated SH5Y were pre-incubated with thrombin (10nM, 50nM and
100nm) with (+) or without (-) dabigatran (250 nM) for 24h h in treatment
medium. Protein expression was measured by western blotting as stated in
section 2.4. (A) Representative GSK3𝛽 levels in RA diﬀerentiated SH5Y cells
preincubated in thrombin (10nM, 50nM and 100nm) with (+) or without (-)
dabigatran (250 nM) for 24h h. The RIPA cell lysate was used, and proteins
were measured by western blot analysis as described in the methods section.
(B) Histograms represent quantiﬁcation after normalization to 𝛽-actin levels.
Data shown are the mean±SEM (n = 3) and signiﬁcance are represented as
∗∗∗p < 0.001compared to untreated control, ++p <+ 0.001 compared to 50nM
thrombin, ###p < 0.001 compared 100nM thrombin.

eral clinical applications including prevention of stroke in patients with
non-valvular atrial ﬁbrillation and the treatment of venous thromboembolism [30,31].
In the present study, we used an in vitro neuronal model the RA differentiated SH-SY5Y human neuroblastoma cells to demonstrate that the
direct thrombin inhibitor dabigatran at a concentration of 250 nM, was
eﬃcacious in preventing thrombin-induced increase in DNA-binding of
the inﬂammation-mediating transcription factor NF𝜅B. We also demonstrated that dabigatran attenuates thrombin-induced expression levels of
signaling protein p38, its phosphorylated form Pp38, APP, AD biomarkers A𝛽 and Tau, as well as proteins involved in their processing or modiﬁcation, namely BACE1 and GSK3𝛽, and the apoptotic protein caspase-3.
Several studies have documented that inhibiting the NF/B pathway is
central to mitigating neuroinﬂammation [15,16]. Our EMSA studies revealed a thrombin concentration-dependent increase in NF/B-DNA binding, with 100nM thrombin displaying the maximum NF/B activation,
which was prevented by dabigatran. Recently we reported that human
endothelial cells exposed to a series of thrombin concentrations like this
study had elevated protein expression of cytokines IL-6, IL-1® and TNF𝛼
[32], that are known to be transcriptionally regulated by NF𝜅B [33], and
we showed that this increase was attenuated by dabigatran [32]. Consistent with our earlier ﬁndings on inﬂammatory proteins, dabigatran
curbed the increased activation of NF/B induced by thrombin which
was evident by decrease in the DNA binding.
Several reports have shown that interaction of thrombin with APP
contributes to cerebral A® formation in AD patients and in other related disorders. Smith and coworkers observed localized immunoreactivity of thrombin at the sites of A® sites in AD brain [34]. Seminal
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Fig 6. Dabigatran alleviates thrombin induced dose-dependent change in mRNA levels BACE 1, APP, Tau and GSK 3𝛽.
RA diﬀerentiated SH5Y were pre-incubated with thrombin (10nM, 50nM and 100nm) with (+) or without (-) dabigatran (250 nM) for 24h h in treatment medium.
mRNA levels of BACE 1, APP, Tau and GSK3𝛽 normalized against 𝛽-actin in qPCR. Histograms represent quantiﬁcation after normalization. Data shown are the
mean ± SEM (n = 3) and signiﬁcance is represented as ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001compared to untreated control, +p <+ 0.01 compared to 50nM thrombin,
#p < 0.01, ##p < 0.01 compared 100nM thrombin.

in NF𝜅B binding as well as down regulation of protein and mRNA levels
of AD associated genes.
This study, although in-vitro, is congruent with a growing literature
documenting the extensive crosstalk between coagulation and inﬂammation. We suggest that repurposing the drug dabigatran, known to decrease inﬂammation and infarct volume in experimental stroke, could
also provide therapeutic beneﬁt against thrombin-driven neuroinﬂammation and downstream pathology in AD.
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